{"id":"W4379470548","doi":"10.1182/bloodadvances.2022009575","title":"Treating relapsed/refractory mature T- and NK-cell neoplasms with tislelizumab: a multicenter open-label phase 2 study","year":2023,"lang":"en","type":"article","venue":"Blood Advances","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"ca_institutions":"Okanagan University College; University of British Columbia, Okanagan Campus; University of British Columbia","funders":"Servier; Italfarmaco; Celltrion; Incyte; BeiGene; Pharmacyclics; MEI Pharma; Regeneron Pharmaceuticals; FibroGen; Gilead Sciences; Bayer HealthCare; Sanofi; MorphoSys; Celgene; Bristol-Myers Squibb; AstraZeneca; Cilag; Astellas Pharma; TG Therapeutics; Amgen; Pfizer; GlaxoSmithKline","keywords":"Refractory (planetary science); Medicine; Multicenter study; Open label; Oncology; Internal medicine; Cancer research; Clinical trial; Biology; Randomized controlled trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008846931,0.0002484921,0.0003890745,0.00008710528,0.0001704506,0.00008487222,0.0001034094,0.0000506988,0.00003214955],"category_scores_gemma":[0.00003135595,0.0001609215,0.00002431305,0.0002529674,0.00004743371,0.000299323,0.0001086843,0.0001105717,0.00005236789],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00003384218,"about_ca_system_score_gemma":0.00005411029,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0000844552,"about_ca_topic_score_gemma":0.0001126048,"domain_scores_codex":[0.9987255,0.00003980777,0.0002197785,0.0004778747,0.0002465869,0.000290406],"domain_scores_gemma":[0.9992154,0.0001595809,0.0001162437,0.0002993304,0.00004934887,0.0001600884],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.003852976,0.06017264,0.7966349,0.0004611722,0.0009907117,0.006283225,0.005036929,0.00001277077,0.003744917,0.00003948129,0.001555813,0.1212144],"study_design_scores_gemma":[0.6178358,0.05334522,0.2316843,0.002009857,0.004811826,0.000554757,0.01782379,0.0006028881,0.02608392,0.00006116104,0.0438021,0.001384361],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9915482,0.003855944,0.000001597479,0.0002170138,0.00008601032,0.001370189,0.00003018355,0.0001291828,0.002761633],"genre_scores_gemma":[0.9944898,0.001022621,0.001807358,0.0001647564,0.00007024068,0.000285469,0.00004901421,0.00003898555,0.002071737],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6139829,"threshold_uncertainty_score":0.6562188,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02035521279004659,"score_gpt":0.3210531474843764,"score_spread":0.3006979346943298,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}